7 results about "Blood coagulation time" patented technology

A blood coagulation time shortening agent for a blood specimen deficient in coagulation factor XII, in activated partial thromboplastin time measurement includes, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit.

The invention relates to the technical field of biomass resource utilization and medical biological materials, in particular to a method for preparing a hemostatic sponge based on sunflower stem pith and application of the hemostatic sponge. The hemostatic sponge is prepared from sunflower stem pith fragments and an adhesive through a deconstruction-recombination technology and meets the requirements of isotropic liquid absorption, non-isotropic liquid absorption and non-isotropic liquid absorption; the difference between the axial blood suction rate and the radial blood suction rate is smaller than or equal to 10%, the shape memory recovery rate within 30 seconds after blood suction is larger than or equal to 85%, and the blood coagulation time is 60-100 seconds. According to the sunflower stem pith-based hemostatic sponge, sunflower byproducts serve as raw materials, the water absorption capacity and the hemostatic efficiency of the sponge are improved by means of the hydrophilicity and the procoagulant characteristic of the sunflower byproducts, and the raw material cost is reduced by 90% or above compared with that of existing synthetic sponge; the sunflower stem pith-based hemostatic sponge is constructed based on deconstruction and structural recombination, the limitation of a natural sunflower stem pith anisotropic microstructure is improved, the sponge has isotropic liquid absorption, the difference between axial and radial blood absorption rates is smaller than or equal to 10%, the sponge has shape memory ability, the sponge is compressed to 50% of the original volume after blood absorption, and the recovery rate is larger than or equal to 85% within 30 s.

The invention belongs to the technical field of application of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating dysfunctional uterine bleeding. Pharmacological experiments prove that Dan'e'fukang can shorten the blood coagulation time and bleeding time of mice, and increase the uterine coefficient, estradiol level and progesterone level of rats without ovulation type dysfunctional uterine bleeding and the VEGF protein expression quantity of endometrial tissues of the rats. The Dan'e Fukang provides more medication choices for clinical treatment of dysfunctional uterine bleeding diseases, and has the advantages of good effect, many years of clinical use experience and high safety.

Provided is a method for accurately measuring coagulation time of blood samples showing various coagulation reactions. The method for measuring blood coagulation time includes measuring coagulation reaction of a sample prepared by mixing a subject specimen and a coagulation time measurement reagent; calculating weighted average time of a calculation target area of a waveform related to coagulation velocity from the resulting measurement data; and determining the weighted average time as blood coagulation time.

An activated partial thromboplastin time measurement reagent contains a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit. A blood coagulation time regulator for a lupus anticoagulant-positive blood specimen or a heparin-containing blood specimen in activated partial thromboplastin time measurement includes, as an active ingredient, a polymer having 2-methacryloyloxyethyl phosphorylcholine as a constitutional unit.

To estimate a cause of extension of coagulation time of the blood of a specimen to be inspected.SOLUTION: A method for estimating a cause of extension of blood coagulation time includes: acquiring a coagulation waveform indicating a change with time of a light amount due to a coagulation reaction of reaction liquid obtained by mixing a specimen to be inspected and an agent (S301b); acquiring a first waveform through before-and-after difference processing on the coagulation waveform (S302b); acquiring first and second fitting waveforms through fitting processing on the coagulation waveform and the first waveform (S303b, S304b); acquiring a third waveform through the before-and-after difference processing on the second fitting waveform (S305b); acquiring first to third normalized waveforms by normalizing light amount axes and time axes of the first and second fitting waveforms and the third waveform (S306b); extracting a feature quantity from each of the first to third normalized waveforms (S307b); and estimating the cause of extension of the coagulation time of the blood of the specimen to be inspected on the basis of a known feature quantity and the extracted feature quantity.SELECTED DRAWING: Figure 3B

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX / F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44 / B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.